<a href="https://pro.campus.sanofi/dam/jcr:9e0d6f97-2ebb-4422-92ab-569b89c7dfe0/praluent%C2%AE-(alirocumab)-prescribing-information-(uk)document.pdf" target="_blank">Praluent® (alirocumab) Prescribing Information (PI link here)</a>

Intensive and sustained LDL-C reduction?1 It’s Praluent® of course

GENERAL-MEDICINES

PRALUENT

DYSLIPIDEMIA

CARDIOLOGY

Praluent® (alirocumab): A PCSK9i That Ticks All the Boxes: Discover key data from the ODYSSEY OUTCOMES trial

Managing LDL-C in post-ACS patients may remain one of cardiology's most persistent challenges — with evidence showing the majority of very high-risk patients are not reaching the ESC/EAS guideline recommended goals on statins alone.6,7
Explore the key data from the ODYSSEY OUTCOMES* trial (N=18,924), which evaluated alirocumab (Praluent®) after acute coronary syndrome. Across the trial, PRALUENT® delivered intensive and sustained LDL-C reduction1, resulting in a significant decrease in major adverse cardiovascular events (MACE)2. In a post hoc analysis§, PRALUENT® also demonstrated its ability to help patients reach LDL-C goals, with 95% of ACS patients achieving LDL-C target levels.6
Key data highlights covered:&nbsp;

LDL-C reduction relative to placebo at 4 months‡‡ - sustained at &gt;54% over 4 years1

Risk reduction in MACE 1,2&nbsp;&nbsp;&nbsp;
 
 (HR 0.85; 95% CI 0.78–0.93;&nbsp;&nbsp;
 
 P=0.0003; ARR 2.0% at 4&nbsp;&nbsp;
 
 years††)&nbsp;&nbsp;
 
 &nbsp;

Long-term safety profile3‡

Patient satisfaction:
Beyond efficacy, the self-administration device was designed with the patient in mind: a hidden needle, a button-free autoinjector, and a dose delivered in ≤20 seconds. 2,4 The ease of usability is also supported by real-world data from the ODYSSEY APRISE† and SYDNEY device study**, indicating patients felt satisfied and confident self-injecting at home.&nbsp;

Patient satisfaction score across&nbsp;
 
 all assessments, indicating&nbsp;
 
 patients felt satisfied and&nbsp;
 
 confident self-injecting at home4

Patient adherence over a mean&nbsp;
 
 72.4-week treatment duration5

PRALUENT® offers flexible dosing to meet individual patient needs — the usual starting dose for PRALUENT® is 75 mg administered subcutaneously once every 2 weeks. Patients requiring larger LDL-C reduction (&gt;60%) may be started on 150 mg once every 2 weeks, or 300 mg once every 4 weeks (monthly), administered subcutaneously.2
If you have any questions or would like further information about Praluent®, please contact Sanofi's customer care team at <a href="mailto:SanofiCares@sanofi.com" target="_blank">SanofiCares@sanofi.com</a>.
Important safety information:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
 
 The most common adverse reactions, at recommended doses, are local injection site reactions (6.1%), upper respiratory tract signs and symptoms (2.0%), and pruritus (1.1%). Most common adverse reactions leading to treatment discontinuation in patients treated with alirocumab were local injection site reactions.2
For more information on Praluent® adverse events please see SmPC.

<h3>Praluent®</h3>
Find more information on Indication, Administration and Mechanism of Action and watch videos about Praluent®.

<h3>Patient Website</h3>
Find resources and support for your patients on Praluent®. Find useful links about how patients can manage their cholesterol.

Footnotes:

References:

Abbreviations:

REZUROCK▼ (belumosudil) is intended for HCPs practising in the United Kingdom.

<h2>PATIENT CASE STUDY</h2>
This case study was provided by Dr Maria Losa Maroto from Queen Elizabeth Hospital NHS Trust, Birmingham and provides an overview of a 42-year-old female patient who suffered with severe lung cGVHD. This patient experienced notable improvements in lung function and overall quality of life after starting REZUROCK treatment, following previous lines of therapy including ECP.

The slide deck above may not display properly on some devices, please access the PDF version of the slides using the button below

<h2>Discover more patient case studies</h2>

Discover all our cGVHD patient case studies&nbsp;

Discover case studies presented at EBMT

Severe Lung GVHD: A Real World Case Study

REZUROCK®▼ (belumosudil) Prescribing Information UK

TRANSPLANT---CORE

REZUROCK

TRANSPLANT

<a href="${link:{uuid:{2a02177b-5764-4cb8-98b6-34b9445e0571},repository:{dam},path:{/Portal/UK/Prescribing-Information/Toujeo-PI-UK.pdf}}}">Toujeo (insulin glargine 300U/mL) Prescribing Information</a>

<h2 style="text-align:center;">A Century of Insulin Experience</h2>

For over 100 years, Sanofi has been committed to the development and production of insulin therapies for people living with diabetes1. Our long-standing heritage in diabetes care has enabled us to build extensive expertise in insulin manufacturing and supply chain management.

<h3 style="text-align:center;">Our Commitment to Toujeo® Insulin Supply in the UK</h3>
Sanofi recognises the clinical importance of maintaining a reliable insulin supply for patients who depend on Toujeo®. We maintain robust contingency plans and strategic inventory management to help ensure continuity of supply across our insulin portfolio.

<h3 style="text-align:center;">Investment in Manufacturing Capabilities</h3>
We continue to invest in our global manufacturing network to enhance production capacity and implement technological advancements. Our manufacturing facilities operate to rigorous quality standards, with regular monitoring and evaluation to maintain compliance with international regulatory requirements.

DIABETES-CORE

OTHER-DIABETES-TOPICS

TYPE-2-DIABETES

TYPE-1-DIABETES

DIABETES

Learn more about Toujeo®

<h2 style="text-align:center;">Evaluating the Environmental Impact Across the Pen Manufacturing Chain</h2>
Toujeo®(insulin glargine U300) pens have been developed with a strong focus on environmental sustainability, supported by a rigorous ISO-certiﬁed Life Cycle Assessment (LCA) conducted in 2024.1 This assessment evaluated the environmental footprint of the product across its entire lifecycle—from raw material sourcing to manufacturing, distribution, use, and disposal. The eco-design approach has led to the below environmental gains, by optimising each step of Toujeo's product lifecycle:1

A key milestone in this journey is the transition to 100% renewable electricity across all insulin manufacturing facilities, reinforcing our commitment to sustainable healthcare delivery.1

<h2 style="text-align:center;">RePen Recycling Scheme</h2>
Sanofi is committed to reducing the environmental impact of diabetes care. The RePen recycling scheme allows patients to return used insulin pens for responsible disposal and recycling.
For more information about the RePen recycling programme and to find your nearest participating location, please visit <a href="https://www.mysanofiinsulin.co.uk/repen/">mysanofiinsulin.co.uk/repen</a>

<h2>Dedicated Support</h2>
Our UK-based customer care team is available to provide support and information regarding our insulin products via <a href="mailto:sanoficares@sanofi.com" target="_blank">sanoficares@sanofi.com</a>.
Our team can provide information on product availability, storage recommendations, and address general enquiries about our insulin products.

Toujeo®

Lantus®

Reference:

Frequently Asked Questions (FAQs)

MAT-XU-2504557 (v4.0) | Date of preparation: July 2026

Sanofi's Commitment to Diabetes with Insulin Supply in the UK

<a href="${link:{uuid:{3c621072-b317-4715-bb3e-c63ceb933735},repository:{dam},path:{/Portal/UK/Prescribing-links/Dupixent-AD-and-PN-GB-PI.pdf}}}">DUPIXENT(dupilumab) Prescribing Information UK</a>

<h2>What is Atopic Dermatitis</h2>
Atopic dermatitis (AD) is a chronic disease driven by persistent underlying inflammation even in nonlesional or normal looking skin 1-3&nbsp;
<ul>
 <li>Atopic dermatitis is an immunological disease where the immune system causes more inflammation than normal</li>
 <li>The overactive immune system under the surface may lead to increased inflammation on the surface and is a contributing factor to the itchy patches on the skin</li>
 <li>Moderate-to-severe AD in adults is a chronic, debilitating inflammatory condition that requires long-term control 1,4</li>
</ul>

<h2>Challenges of treating Atopic Dermatitis</h2>
Atopic dermatitis (AD) is a chronic disease driven by persistent underlying Type 2 inflammation 1-3&nbsp;
Even skin that appears non-lesional on the surface is clearly distinct from normal skin:1-3&nbsp;

Non-lesional skin in AD has been shown to have cutaneous expansion of T cells and abnormalities that are largely similar to lesional AD skin. This highlights the importance of early identification and treatment of patients with this condition.&nbsp;

SPECIALTY-CARE

DUPIXENT

IMMUNOLOGY

ATOPIC-DERMATITIS

DERMATOLOGY

Tool to identify an uncontrolled AD patient&nbsp;

<ul>
 <li>In the UK, ciclosporin is the only conventional systemic immunosuppressant approved for the management of severe AD in adults5.&nbsp;Other systemic immunosuppressants are used off-label, despite limited evidence supporting their efficacy and safety6-8 </li>
 <li>Systemic immunosuppressants exert broad suppression of the immune system, while immunomodulators target specific immune pathways/cell types, thereby reducing off-target effects9 </li>
 <li>Broad-acting immunosuppressants are associated with a range of toxicities and side effects that limit their long-term use and require routine laboratory monitoring to minimise the risks 6,7,10,11</li>
</ul>

AD experts* proposed four types of treatment failure which patients with AD may experience despite appropriate dose, duration and adherence to a therapeutic agent12:&nbsp;
<ol>
 <li>Inadequate clinical improvement12&nbsp;</li>
 <li>Failure to achieve stable long-terms disease control12</li>
 <li>Adverse events or poor tolerability with current treatment12</li>
 <li>Failure to relieve burden of disease† 12</li>
</ol>

*A steering committee that consisted of a multi-disciplinary group of AD experts, including 8 dermatologists, two allergists and a patient advocacy group representative. This group met to identify and prioritise a number of essential questions concerning the evaluation and management of moderate-to-severe AD in the era of biologic therapies&nbsp;
†Presence of ongoing impairment (e.g., pruritus, pain, loss of sleep, and poor quality of life) while on treatment

<h2>The Role of Type 2 Inflammation&nbsp;</h2>
Dysregulated signaling of IL-4 and IL-13—two key drivers of type 2 inflammation—plays an important role in the pathogenesis of AD&nbsp; 13-18&nbsp;
IL-4 is a key upstream modulator of Th2 response, promoting a positive feedback loop that contributes to dysregulated secretion of IL-4, IL-13, and IL-31 #&nbsp;

IL-4 and IL-13 have overlapping roles in Type 2 inflammation:

<h3>Management approaches in AD should address the persistent underlying Type 2 inflammation&nbsp;&nbsp;</h3>
<ul>
 <li>Three types of immune response play a natural protective role against different pathogens, the Type 2 immune response drives AD specifically 1-3&nbsp;</li>
 <li>Broad spectrum immunosuppressants do not specifically inhibit Type 2 inflammatory pathway&nbsp;19-21&nbsp;</li>
 <li>Non-specific mechanisms may result in unwanted side effects and the need for lab monitoring, limiting traditional systemic treatments as long-term therapeutic options 1,19-24&nbsp;</li>
</ul>

<h3>DUPIXENT directly targets the underlying type 2 inflammation involved in AD.</h3>

Read to learn more about Atopic Dermatitis and its underlying causes 

DUPIXENT (dupilumab) Prescribing Information UK

An Introduction to Atopic Dermatitis

A short animation for bone specialists, including orthopaedic and rheumatology, to support the diagnosis of Gaucher disease.&nbsp;

RARE-DISEASE

GAUCHER

Gaucher Bone Diagnosis Support

<h2>REZUROCK'S Mode of Action</h2>
Dr Francesca Kinsella explains how REZUROCK targets both the inflammatory and fibrotic processes of cGVHD through selective inhibition of the ROCK2 pathway.

Understanding the Mode of Action of REZUROCK▼(belumosudil)

<h2>Why is this important?</h2>

<h3>Early onset and complexity of fibrosis in cGvHD</h3>
Fibrosis in cGvHD may happen earlier than expected.
<ul>
 <li>Inflammation and fibrosis can both occur within the first year post allogenic&nbsp;hematopoietic stem&nbsp;cell transplantation (alloHSCT), but sometimes develop many years after.1-2</li>
 <li>The exact relationship between inflammation and fibrosis is complex and not yet fully understood.3</li>
 <li>Fibrosis may be viewed as a natural consequence of inflammation, but in fact,&nbsp;research suggests it may begin developing prior to&nbsp;any symptoms of cGvHD.4-6</li>
</ul>

<h2>The need for early intervention</h2>
Despite the heterogeneity of cGvHD presentation, the defining features are inflammation and fibrosis1,3&nbsp;which can affect multiple organs.&nbsp;
The condition can affect the skin, liver, lungs, eyes and gastrointestinal system, among others.
Acting as early as possible to target both the fibrotic and inflammatory components of cGvHD could be crucial in appropriate patients.7,9

Gain a deeper understanding of the mechanisms behind cGvHD, including its key drivers - inflammation and fibrosis. (For full interactivity, download&nbsp;and view in Adobe Acrobat).

Abbreviations

References

<a href="https://pro.campus.sanofi/dam/jcr:11530ca1-d3ac-4871-a8dc-fcc2953df330/Toujeo%20PI.pdf" target="_blank">Toujeo® (insulin glargine 300 units/ml) Prescribing Information</a> <a href="https://pro.campus.sanofi/dam/jcr:97e86e26-07fe-49e8-b6f3-31758c4a1495/Lantus%20PI.pdf">Lantus® (insulin glargine 100 units/ml) Prescribing Information</a>
With the discontinuation of Levemir® (insulin detemir) this December, decisions around which alternative basal insulin to initiate or switch patients to are becoming increasingly important.&nbsp;
The following guidance reflects the joint recommendations of the Association of British Clinical Diabetologists (ABCD) and Primary Care Diabetes &amp; Obesity Society (PCDO) on the discontinuation of Levemir, applied to initiating and switching patients to Toujeo® (insulin glargine 300 units/mL) in clinical practice.1 Toujeo® remains one of the preferred options in certain patient circumstances.1

<h2>Starting patients on Toujeo®2</h2>
Toujeo® is a basal insulin for once daily administration at any time of the day, preferably at the same time every day. When needed, patients can administer Toujeo® up to 3 hours before or after their usual time of administration. The dose regimen (dose and timing) should be adjusted according to individual response.2&nbsp;
Toujeo® is indicated for the treatment of diabetes mellitus in adults, adolescents and children from the age of 6 years.2

Download Starting Toujeo® Checklist

<h2>Switching from different basal insulins to Toujeo®2</h2>
<h3>Whenever switching insulins, close metabolic monitoring is recommended during the switch and in the initial weeks thereafter, with potential dose adjustments and adjustments required to the patients’ treatment regimen.</h3>

Switching from twice-daily Levemir to Toujeo®2

Switching from once-daily Levemir to Toujeo®2

Switching from insulin glargine U100 to Toujeo®2

<h2>Practical Implementation1</h2>
Time pressures in clinical practice bring competing demands. The guidance below provides key considerations to support patients at the different stages of their transition.

<ul>
 <li>Check the DHSC Medicines Supply Notiﬁcation and availability via the SPS Medicines Supply Tool. &nbsp;</li>
 <li>People with allergies to alternative insulins should be referred to local allergy or diabetes services as required.</li>
 <li>Evaluate co-morbidities, and prioritise those in high-risk groups, such as those below: 
 <ul>
 <li>Impaired hypoglycaemia awareness</li>
 <li>High glucose variability on CGM, history of severe hypoglycaemia or recurrent diabetic ketoacidosis (DKA)</li>
 <li>Evidence of lipohypertrophy at injection sites</li>
 <li>Frailty and/or older age</li>
 <li>Children and adolescents</li>
 <li>Renal or severe hepatic impairment</li>
 <li>Cognitive or functional impairment</li>
 <li>Learning diﬃculties or low health literacy</li>
 <li>Visual impairment and manual dexterity problems</li>
 <li>High alcohol intake or binge drinking</li>
 <li>High level of physical activity</li>
 </ul></li>
</ul>

Pre-switch¹

<ul>
 <li>As part of the clinical review, assess whether the current insulin regimen in type 2 diabetes could be optimised by introducing / switching to diﬀerent insulin types (e.g., rapid-acting, or mixed insulin) or by incorporating non-insulin therapies.</li>
 <li>When switching between insulins, there can be diﬀerences between absorption, potency, and action proﬁle, therefore consider reducing doses by 10-20% to avoid the initial risk of hypoglycaemia.</li>
 <li>If lipohypertrophy is detected, considerable dose adjustment is often required when changing injection sites, seek advice and guidance as necessary if unsure.</li>
 <li>When prescribing new insulins, ensure any change in device type is explained to the patient with written product information provided.</li>
 <li>For those with very erratic glucose levels, or disproportionately high insulin doses, assess injection technique and check for evidence of lipohypertrophy at injection sites.</li>
 <li>Education and support should be provided to help individuals self-adjust doses post-switch, where appropriate, along with a check of understanding of sick day rules.</li>
 <li>Ensure adequate safety netting, advising patients to report any concerns about glucose levels after following provided dose adjustment guidance.&nbsp;</li>
</ul>

During the review¹

<ul>
 <li>Risk of glucose instability is elevated during insulin changes. A clinical review with CBG/CGM data is helpful.</li>
 <li>Monitoring should rely on capillary blood glucose (CBG) at least four times daily, CGM, and ketone monitoring (where appropriate)—not HbA1c alone.</li>
 <li>People living with diabetes should be reviewed at 2-3 weeks to support with dose titration, as necessary. For those at higher risk of dysglycaemia aim for close clinical review within 1-2 weeks of change where possible.</li>
 <li>If there is uncertainty seek advice and guidance or refer to community / specialist diabetes services as per locally agreed pathways.&nbsp;</li>
</ul>

Post-switch¹

<h2>Dedicated Support&nbsp;</h2>
Our UK-based customer care team is available to provide support and information regarding our insulin products via <a href="mailto:sanoficares@sanofi.com" target="_blank">sanoficares@sanofi.com</a>. &nbsp; 
 This includes information on product availability, storage recommendations, and address general enquiries about our insulin products.&nbsp; 
 Patient resources and demonstration devices can be requested via <a href="mailto:sanoﬁcares@sanoﬁ.com" target="_blank">sanoﬁcares@sanoﬁ.com</a> or printed from <a href="https://www.mysanofiinsulin.co.uk/" target="_blank">mysanoﬁinsulin.co.uk</a>.&nbsp;

<h2>RePen Recycling Scheme</h2>
Sanofi is committed to reducing the environmental impact of diabetes care. The RePen recycling scheme allows patients to return used insulin pens for responsible disposal and recycling.&nbsp; 
 For more information about the RePen recycling programme and to find your nearest participating location, please visit <a href="https://www.mysanofiinsulin.co.uk/repen/" target="_blank">mysanofiinsulin.co.uk/repen</a>.&nbsp;

<h5>References</h5>
<ol>
 <li>Newland-Jones P, Beba H, Kanumilli N, Kelly B, Lindsay R, Mehta F, Milne N, Platts J, Tahir W, Dhatariya K (2025) Discontinuation of Levemir® (Insulin detemir) Flexpen® and Penfill® Clinical Guideline. Primary Care Diabetes &amp; Obesity Society and Association of British Clinical Diabetologists. Available at: <a href="https://pcdosociety.org/guidance/levemir-discontinuation" target="_blank">https://pcdosociety.org/guidance/levemir-discontinuation</a> [Accessed 7 April 2026]</li>
 <li>Sanofi. Toujeo® 300 units/mL solution for injection in a pre-filled pen - Summary of Product Characteristics (SmPC) 2024.&nbsp;</li>
</ol>
&nbsp;
MAT-XU-2504556-2.0-04/2026

A practical guide for initiating or switching patients to a new insulin

How to Start and Switch Insulin: an HCP's guide

Beyfortus has been studied in a robust clinical trial program across a broad infant population, including those born very to moderately pre-term (GA ≥29 to &lt;35 weeks), late pre-term and at term (GA ≥35 weeks)1-3
<h3>Explore Beyfortus clinical trial data explained by Prof. Saul N Faust and Dr. Katrina Cathie</h3>

Beyfortus®▼ (nirsevimab)

VACCINES

RESPIRATORY-SYNCYTIAL-VIRUS

Efficacy & Safety Profile

Professor Saul N Faust
 
 Professor of Paediatric Immunology &amp; Infectious Diseases; NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton, NHS Foundation Trust; Faculty of Medicine and Institute for Life Sciences, University of Southampton, Southampton.

Dr Katrina Cathie
 
 Consultant Paediatrician; Associate Director, NIHR Southampton Clinical Research Facility; Southampton Children's Hospital Speciality Group Clinical Lead for Paediatrics in Wessex, Chair of the UK Children's General Paediatrics Clinical Studies Group.

<h2>Beyfortus showed efficacy against RSV disease in infants1-3</h2>
Incidence of MA RSV LRTI (inclusive of hospitalisations) through 150 days post injection
 
 (primary endpoint was met)1–3

Phase 2b and Phase 3 pivotal clinical trials were randomised, double-blind, controlled trials.2,3 Phase 2b n= 1,453 and phase 3 n=1,490. Efficacy for MA RSV-LRTI based on relative risk reduction against placebo was adjusted for age at randomisation and hemisphere. Medically attended&nbsp;(MA) includes all healthcare provider visits such as physician’s office, urgent care, emergency room, and hospitalisations.

<h2>Beyfortus demonstrated a reduction in RSV hospitalisation vs placebo1-3</h2>
Incidence of hospitalisation for RSV-related LRTI (secondary endpoint) in pivotal clinical
 
 trials1–3

The incidence of RSV hospitalisation showed consistent results in a close to real-world settings*4
 
 &nbsp;

* The Hospitalised RSV Monoclonal Antibody Prevention (HARMONIE) study is a large, multi-country European interventional clinical trial aiming to determine the efficacy and safety of a single intramuscular dose of nirsevimab, with data collected in a real-world setting during the 2022-2023 RSV season. The trial recruited more than 8,000 infants and took place at nearly 250 sites across France, Germany and the United Kingdom.&nbsp;
**Compared with the primary analysis reported by Drysdale SB et al. 2023, two participants in the standard care group and one participant in the nirsevimab group were excluded.
 
 &nbsp;

<h2>Consistent safety profile across multiple infant cohorts</h2>
Safety has been studied in a broad population, including healthy pre-term and term babies and those at higher risk of RSV-related LRTI.1-3,5&nbsp;
The safety profile was similar to placebo in the phase 2b and phase 3 studies.2-3,5
The most frequent adverse reaction was rash (0.7%) occurring within 14 days post dose. Most cases were mild to moderate in intensity. Additionally, pyrexia and injection site reactions were reported at a rate of 0.5% and 0.3% within 7 days post dose, respectively.&nbsp;
 
 Injection site reactions were non-serious.1
Infants at higher risk for severe RSV&nbsp;
 
 The safety profile was comparable to palivizumab in first RSV season and consistent with the safety profile in term and preterm infants (≥29 GA weeks).1,5,a
Infants who remain vulnerable to severe RSV in their second season
 
 The safety profile was consistent with the safety profile observed during their first RSV season.1
For the full list of adverse events please refer to the Beyfortus SmPC.&nbsp;
 
 &nbsp;

BEYFORTUS PROFILE

Read more about effectiveness and public health impact

REAL-WORLD EVIDENCE&nbsp;

Sign up to receive the latest
<div>
 information about&nbsp;Beyfortus®
</div>

Abbreviations and footnotes

Prescribing Information UK

<a href="https://pro.campus.sanofi/dam/jcr:11530ca1-d3ac-4871-a8dc-fcc2953df330/Toujeo%20PI.pdf" target="_blank">Toujeo® (insulin glargine 300 units/ml) Prescribing Information</a>&nbsp;
Effective Type 2 diabetes management involves balancing efficacy and safety considerations. When prescribing basal insulin (BI), treatment options may be associated with different glycaemic outcomes.1 The BRIGHT study provides valuable head-to-head data comparing Toujeo® (insulin glargine 300 U/mL) and insulin degludec 100 U/mL.1 &nbsp;
<h2>BRIGHT Study: Direct Comparison &nbsp;</h2>
The BRIGHT trial is a randomised controlled study designed to directly compare Toujeo® (insulin glargine 300 U/mL) with degludec 100 U/mL in insulin-naïve adults with type 2 diabetes (T2D).1 This 24-week, multicentre study enrolled 929 participants.1&nbsp;

<h2>Comparable Glycaemic Efficacy: HbA1c Outcomes at Week 24</h2>
Both Toujeo® and insulin degludec 100 U/mL were associated with reductions in HbA1c over 24 weeks. Toujeo® demonstrated non-inferiority to insulin degludec 100 U/mL for the primary efficacy endpoint.1&nbsp;

<h2>Hypoglycaemia Rates</h2>
Over the full 24-week study period, the incidence of anytime (24-h) severe and/or documented hypoglycaemia (&lt;3.0 mmol/L) was comparable between Toujeo® and insulin degludec 100 U/mL (RR (95% CI): 0.69 (0.45 to 1.08); p=0.104)¹ During the initial 12-week titration period, hypoglycaemia outcomes were evaluated separately for Toujeo® and insulin degludec 100 U/mL and showed lower confirmed rates of anytime (24-h) severe and/or documented hypoglycaemia (&lt;3.0 mmol/L) with Toujeo® (RR (95% CI): 0.57 (0.34 to 0.97); p=0.038).1 &nbsp;

<h2>Conclusion</h2>
The initial weeks of basal insulin therapy represent a crucial window that may influence long-term treatment success.2 People with diabetes who experienced hypoglycaemia during the first months of insulin therapy were more likely to experience recurrent episodes and had a higher risk of hypoglycaemia and basal insulin discontinuation.2,3 Strategies to reduce hypoglycaemia risk during titration may help influence subsequent insulin dosing behaviour and longer-term safety outcomes.2,3
In this randomised study, the BRIGHT trial evaluated glycaemic and hypoglycaemic outcomes in a head-to-head comparison of Toujeo® (insulin glargine 300U/mL) and insulin degludec 100 U/mL in insulin-naïve patients with type 2 diabetes. Over the 24-week study period, non-inferiority for the primary HbA1c endpoint was demonstrated, with additional analyses describing hypoglycaemia outcomes during the titration and maintenance phases.1,3&nbsp;
&nbsp;
Abbreviations &nbsp;
ARR, absolute risk reduction; CI, confidence interval; HbA1c, glycated haemoglobin; RR, rate ratio; T2D, type 2 diabetes&nbsp;

Efficacy and safety considerations are essential for effective Type 2 diabetes management.

The BRIGHT Study: Comparing Toujeo® (insulin glargine 300 U/mL) and Insulin Degludec 100 U/mL  

Toujeo® (insulin glargine 300 U/mL) Prescribing Information UK

TOUJEO

To read this content, please activate your Sanofi Campus account via the email we've sent to you.

If you didn't receive our first email at {email} to confirm your account you can request a new one below. If you don't see it, you may need to check your spam folder.

title

In order to see relevant content, tell us what you are interested in

Title

Quick Summary

This website is for healthcare professionals only.

Welcome to BP Sanofi Campus

Create new password

complete your profile to help us provide you with content that's relevant to you.

Your profile is incomplete

Development of ADCT involved literature review as well as interviews with patients and physicians, and was funded by Sanofi and Regeneron.

The ADCT gives a measure of how controlled your patient’s eczema is. Use these 6 concise questions to evaluate all dimensions of atopic dermatitis control.

Atopic dermatitis, a type of eczema, may be affecting your patient’s life in more ways than you know.

Enjoy more exclusive content{newline}by <a>registering today</a>

MAT-XU-2300297 (v3.0) - Date of preparation: October 2023

MAT-XU-2305062 (v1.0) - Date of preparation: November 2023

MAT-XU-2300297 (v3.0) Date of Preparation: October 2023

MAT-XU-2305047 (v1.0) - Date of preparation: November 2023

Already have an account? <a>Sign in here</a>

Best practices on optimising patient care

Get a customised view of the topics that you're interested in, along with the ability to save content to watch or read at a later date.

Unlimited access to premier content, white papers, case studies, research papers, webinars, training, and up-to-date scientific medical resources.

Personalised content based on your areas of interest

Connect and stay up-to-date with peers in your area of speciality and topics of interest through free events and leadership forums.

Please sign in to continue and read the full article

Please sign up to continue reading the full article.

We respect your privacy and will not share your information with any 3rd parties.

Topical guides written specifically for patients

Unlimited access to the latest patient guide guides and resources. Share content with your patients with easy-to-use online tools.

Please complete your profile to read the content.

Your profile is not validated yet. Please verify your inbox.

Restricted Access

Share via {platform} (opens email client)

Cause And Symptoms

Complications

Diagnosis And Treatment

Overview

Prevention

We can't find the page you're looking for

You are going to a website that is not operated by Sanofi. Sanofi has no control over the content or availability of linked sites or resources, and accepts no liability or responsibility for them or for any loss or damage that may arise from your use of them. Please ensure that you read the legal and privacy policy sections of any third-party site to which you link.

You are about to leave Sanofi Campus website.

You are now leaving this site to visit a partner website.

Thank you for visiting COPD Sanofi Campus.

Welcome to COPD Sanofi Campus.

Welcome to COPD Sanofi Campus

Welcome to CSU Sanofi Campus

Please refresh the page to access the content

Sorry, something went wrong

The page you are looking for may be under maintenance, or the link may be incorrect.

Sorry, we can't find this page

There are no upcoming events

Showing {start}–{end} of {total} events

Event details

Check back later for upcoming events, or browse all available events across therapeutic areas.

There are no events scheduled for this therapeutic area

Something went wrong

Try a different keyword, date range, or venue.

No matching events

Registration information

Success! We've received your request

You are going to a website that is not operated by Sanofi or a Sanofi website where the terms of use may differ. For external websites, Sanofi has no control over the content or availability of linked sites or resources, and accepts no liability or responsibility for them or for any loss or damage that may arise from your use of them. Please ensure that you read the legal and privacy policy sections of any third-party or Sanofi sites.

You are about to leave Sanofi campus website.

You are about to leave Campus.sanofi/uk.

Privacy Notice Update | We have updated our Privacy Notice for Healthcare Professionals to improve your experience collaborating with us, maintain high standards of privacy and ultimately strengthen the trust you place in us. Key improvements include enhanced clarity on why and how Sanofi processes your personal data.

Thank you for registering. Before we get started, we need to confirm your email address to ensure that we have the correct information.

Please follow these steps to complete your registration:

Would you like to receive future text messages about Beyfortus updates?

Would you also like to receive future messages and updates about Beyfortus?

Do you want to participate in the Beyfortus Reservation Program?

What information are you interested in learning more about? (Optional)

Are you enrolled in CENRIFKI REMS?

Request a visit from your local ALPROLIX representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Request a visit from your local ALTUVIIIO representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Request a visit from your local QFITLIA representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Sign up to schedule an office visit with your ALPROLIX® Representative or receive updates about ALPROLIX. Please complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Sign up to schedule an office visit with your local Sanofi representative and/or to receive updates about Qfitlia. Please complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required (unless otherwise specified).

All fields are required. (unless otherwise specified)

Title should not exceed 100 characters

Enter your title

This site is intended for UK healthcare professionals only and contains information on Sanofi UK's medicines, educational resources and more. Please click the appropriate button below. By entering this site, you are confirming that you are a UK healthcare professional. This site contains promotional information. Some content may only be relevant to HCPs practising in Great Britain (England, Scotland and Wales) according to product availability. This website is optimised for desktop use, and some features may perform differently on mobile devices.

MAT-XU-2300297 (v7.0) - Date of Preparation: July 2025

Welcome to Sanofi Campus UK

Welcome to ITP Sanofi Campus

This content is only available to registered users. Please sign in or register to view this content.

Please Sign In

Review the materials in your cart before checkout.

Browse and order materials for your practice.

Filters

Materials

Cart

Checkout

Email verification

You're seeing a preview of the portal. Clear your cookies (by closing your browser window for example) to go back to public mode.

We've updated our privacy notice to better protect your data and enhance your experience. Please take a moment to review the changes by <privacyNewTab>clicking here</privacyNewTab>. Your privary matters for us. Please click on continue to confirm you have read the new privacy notice.

Privacy Notice Update

Communication consent

My Consent

Password

Confirm password

{resultsCount, plural, one {result} other {results}}

Please sign in to access to the results

You need to sign-in to your account in order to access medical content.

To access the results, please register in under 1 minute

You are now leaving the Sanofi content section of our site and entering the external medical bibliographic search content section.

You are entering to the External Scientific Content Site

You are now leaving the external medical bibliographic search section of our site and entering the Sanofi content section.

Latest Articles